344 related articles for article (PubMed ID: 38003594)
1. Targeting Epigenetic Regulators with HDAC and BET Inhibitors to Modulate Muscle Wasting.
Nevi L; Pöllänen N; Penna F; Caretti G
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003594
[TBL] [Abstract][Full Text] [Related]
2. Shared and Divergent Epigenetic Mechanisms in Cachexia and Sarcopenia.
Yedigaryan L; Gatti M; Marini V; Maraldi T; Sampaolesi M
Cells; 2022 Jul; 11(15):. PubMed ID: 35892590
[TBL] [Abstract][Full Text] [Related]
3. The role of beta-adrenoceptor signaling in skeletal muscle: therapeutic implications for muscle wasting disorders.
Koopman R; Ryall JG; Church JE; Lynch GS
Curr Opin Clin Nutr Metab Care; 2009 Nov; 12(6):601-6. PubMed ID: 19741516
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive proteome analysis of human skeletal muscle in cachexia and sarcopenia: a pilot study.
Ebhardt HA; Degen S; Tadini V; Schilb A; Johns N; Greig CA; Fearon KCH; Aebersold R; Jacobi C
J Cachexia Sarcopenia Muscle; 2017 Aug; 8(4):567-582. PubMed ID: 28296247
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms and treatment targets of muscle wasting and cachexia in heart failure: an overview.
Ebner N; Elsner S; Springer J; von Haehling S
Curr Opin Support Palliat Care; 2014 Mar; 8(1):15-24. PubMed ID: 24452279
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic targeting of bromodomain protein BRD4 counteracts cancer cachexia and prolongs survival.
Segatto M; Fittipaldi R; Pin F; Sartori R; Dae Ko K; Zare H; Fenizia C; Zanchettin G; Pierobon ES; Hatakeyama S; Sperti C; Merigliano S; Sandri M; Filippakopoulos P; Costelli P; Sartorelli V; Caretti G
Nat Commun; 2017 Nov; 8(1):1707. PubMed ID: 29167426
[TBL] [Abstract][Full Text] [Related]
7. Drugs of Muscle Wasting and Their Therapeutic Targets.
Sakuma K; Yamaguchi A
Adv Exp Med Biol; 2018; 1088():463-481. PubMed ID: 30390265
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D, muscle recovery, sarcopenia, cachexia, and muscle atrophy.
Garcia M; Seelaender M; Sotiropoulos A; Coletti D; Lancha AH
Nutrition; 2019 Apr; 60():66-69. PubMed ID: 30529188
[TBL] [Abstract][Full Text] [Related]
9. Skeletal muscle loss: cachexia, sarcopenia, and inactivity.
Evans WJ
Am J Clin Nutr; 2010 Apr; 91(4):1123S-1127S. PubMed ID: 20164314
[TBL] [Abstract][Full Text] [Related]
10. Skeletal muscle wasting after a severe burn is a consequence of cachexia and sarcopenia.
Song J; Clark A; Wade CE; Wolf SE
JPEN J Parenter Enteral Nutr; 2021 Nov; 45(8):1627-1633. PubMed ID: 34296448
[TBL] [Abstract][Full Text] [Related]
11. F-BOX proteins in cancer cachexia and muscle wasting: Emerging regulators and therapeutic opportunities.
Sukari A; Muqbil I; Mohammad RM; Philip PA; Azmi AS
Semin Cancer Biol; 2016 Feb; 36():95-104. PubMed ID: 26804424
[TBL] [Abstract][Full Text] [Related]
12. Emerging roles for histone deacetylases in age-related muscle atrophy.
Walsh ME; Van Remmen H
Nutr Healthy Aging; 2016 Oct; 4(1):17-30. PubMed ID: 28035339
[No Abstract] [Full Text] [Related]
13. MicroRNAs as potential therapeutic targets for muscle wasting during cancer cachexia.
Sannicandro AJ; McDonagh B; Goljanek-Whysall K
Curr Opin Clin Nutr Metab Care; 2020 May; 23(3):157-163. PubMed ID: 32073414
[TBL] [Abstract][Full Text] [Related]
14. Loss of muscle mass: Current developments in cachexia and sarcopenia focused on biomarkers and treatment.
Drescher C; Konishi M; Ebner N; Springer J
Int J Cardiol; 2016 Jan; 202():766-72. PubMed ID: 26474466
[TBL] [Abstract][Full Text] [Related]
15. Valproic acid attenuates skeletal muscle wasting by inhibiting C/EBPβ-regulated atrogin1 expression in cancer cachexia.
Sun R; Zhang S; Hu W; Lu X; Lou N; Yang Z; Chen S; Zhang X; Yang H
Am J Physiol Cell Physiol; 2016 Jul; 311(1):C101-15. PubMed ID: 27122162
[TBL] [Abstract][Full Text] [Related]
16. Gene Ontology (GO)-Driven Inference of Candidate Proteomic Markers Associated with Muscle Atrophy Conditions.
Stalmach A; Boehm I; Fernandes M; Rutter A; Skipworth RJE; Husi H
Molecules; 2022 Aug; 27(17):. PubMed ID: 36080280
[TBL] [Abstract][Full Text] [Related]
17. Sarcopenia, cachexia, and muscle performance in heart failure: Review update 2016.
Saitoh M; Ishida J; Doehner W; von Haehling S; Anker MS; Coats AJS; Anker SD; Springer J
Int J Cardiol; 2017 Jul; 238():5-11. PubMed ID: 28427849
[TBL] [Abstract][Full Text] [Related]
18. A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma.
Kling MJ; Kesherwani V; Mishra NK; Alexander G; McIntyre EM; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
J Exp Clin Cancer Res; 2022 Nov; 41(1):321. PubMed ID: 36357906
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanism of sarcopenia and cachexia: recent research advances.
Sakuma K; Aoi W; Yamaguchi A
Pflugers Arch; 2017 Jun; 469(5-6):573-591. PubMed ID: 28101649
[TBL] [Abstract][Full Text] [Related]
20. Deliberation on debilitating condition of cancer cachexia: Skeletal muscle wasting.
Dave S; Patel BM
Fundam Clin Pharmacol; 2023 Dec; 37(6):1079-1091. PubMed ID: 37474262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
